Peptide stack evidence reviews
21 combination evidence reviews. Each review carries an A–X evidence grade, human-data status, direct-vs-inferred combination labelling, translational-risk and regulatory-sensitivity flags. This is not a protocol library — it is an evidence library.
What every stack page contains
- An evidence dashboard at the top: A–X grade, human-data status, direct combination evidence, translational risk, regulatory sensitivity, mechanism category, last reviewed.
- A “not a protocol” notice before any reported study-dose context.
- Mechanism overview for each peptide in the combination.
- Reported study-dose context — descriptive, not instructional. See responsible information policy.
- Safety signals and UK regulatory context.
- Translational limitations and known evidence-base caveats.
- Reference list with PubMed / DOI links; verified citations also rendered as evidence cards.
- FAQs and last-reviewed date.
Conservative default grading
Most stacks on this site sit at Grade C or lower. The combination is the claim, and the combination is rarely directly studied — most stacks are inferred from the monotherapy literature of their components. See: direct vs inferred stacks.
UK regulatory reminder
Most peptides discussed are not approved medicines in the UK. Tirzepatide (Mounjaro) is the principal MHRA-licensed compound referenced; others are unapproved or POM-adjacent. See: UK regulation hub, POM advertising rules, medical disclaimer.
Loading stacks…